MCHR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL94121	1.00	20/20
SCHEMBL94154	1.00	20/20
SCHEMBL94163	1.00	20/20
SCHEMBL94164	1.00	20/20
SCHEMBL94171	1.00	20/20
SCHEMBL94177	1.00	20/20
SCHEMBL94178	1.00	20/20
SCHEMBL94181	1.00	20/20
SCHEMBL94193	1.00	20/20
SCHEMBL94201	1.00	20/20
SCHEMBL94202	1.00	20/20
SCHEMBL94214	1.00	20/20
SCHEMBL94215	1.00	20/20
SCHEMBL94216	1.00	20/20
SCHEMBL94218	1.00	20/20
SCHEMBL94219	1.00	20/20
SCHEMBL94222	1.00	20/20
SCHEMBL94223	1.00	20/20
SCHEMBL94232	1.00	20/20
SCHEMBL94244	1.00	20/20

Clinical trials — most relevant to MCHR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Genotype on Resting State Connectivity During Methamphetamine Administration	PHASE4	COMPLETED
Investigating the Potential Role of Aerosolized Retinoic Acid, a Potent Vitamin A Metabolite for Treating COVID-19 Anosmia and Retinoic Acid Insufficiency .A Novel Approach for Regaining Sense of Smell.	PHASE4	UNKNOWN
Medication, Weight Gain and GI Hormones	PHASE4	COMPLETED
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep	PHASE3	COMPLETED
Safety and Efficacy Study of Ramelteon in Subjects With Chronic Insomnia	PHASE3	COMPLETED
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome	PHASE2	COMPLETED
Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity	PHASE2	COMPLETED
Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers	PHASE2	COMPLETED
ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)	PHASE2	COMPLETED
Carbidopa-levodopa in Neovascular AMD	PHASE2	COMPLETED
Efficacy and Safety of Ramelteon Combined With Gabapentin in Treating Patients With Insomnia	PHASE2	COMPLETED
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss	PHASE2	COMPLETED
Effects of RM-493 on Energy Expenditure in Obese Individuals	PHASE1	COMPLETED
Postoperative Cognitive Dysfunction in Elderly and it's Relation With Sleep Disorders and Melanin Concentrating Hormone	nan	NOT_YET_RECRUITING
Brain-Derived Neurotrophic Factor in Obesity and Brain Function	nan	COMPLETED
Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment	nan	RECRUITING
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy	nan	COMPLETED
Molecular Evaluation of TAAR1 and JAK/STAT Pathway in Hidradenitis Suppurativa	nan	COMPLETED
Insulin Detemir in Obesity Management	nan	ACTIVE_NOT_RECRUITING
MTNR1B SNP*Food Timing Interaction on Glucose Control	nan	COMPLETED
Auricular Vagus Stimulation in Obesity	nan	ACTIVE_NOT_RECRUITING
Assessing Obesity Related Risk Factors in Adult Population: A Genetic and Behavioral Study	nan	ENROLLING_BY_INVITATION
Glucose Tolerance, Meal Timing and MTNR1B	nan	COMPLETED
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
Sequencing of 14 Genes From Leptin Melanocortin Pathway in Severe Obesity in Childhood.	nan	UNKNOWN
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia	nan	UNKNOWN
PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)	nan	COMPLETED
Clinical, Cellular, and Molecular Investigation Into Oculocutaneous Albinism	nan	COMPLETED
Melanocortin 4 Receptor Mutations and Obesity-associated Diseases	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a MCHR1 binder may also engage these)

Protein	Name	Similarity
Q8MJ89	—	1.000	Q8MJ89 →
Q5IJ49	—	1.000	Q5IJ49 →
P97639	—	1.000	P97639 →
Q9MZ01	—	1.000	Q9MZ01 →
Q8JZL2	—	1.000	Q8JZL2 →
MCHR2	Melanin-concentrating hormone receptor 2	0.990	landscape →
Q8SQ54	—	0.987	Q8SQ54 →
Q8MJ88	—	0.985	Q8MJ88 →
Q9WV08	—	0.982	Q9WV08 →
Q9JHG3	—	0.979	Q9JHG3 →
Q9Z0Z6	—	0.979	Q9Z0Z6 →
APLNR	Apelin receptor	0.977	landscape →
F1R332	—	0.977	F1R332 →
E7F7V7	—	0.977	E7F7V7 →
P25102	—	0.977	P25102 →
Q0VDU3	—	0.977	Q0VDU3 →
O97666	—	0.977	O97666 →
P56412	—	0.976	P56412 →
Q9BG77	—	0.976	Q9BG77 →
P32303	—	0.975	P32303 →
P35351	—	0.975	P35351 →
P60021	—	0.974	P60021 →
P49685	—	0.974	P49685 →
P35374	—	0.974	P35374 →
O97663	—	0.974	O97663 →
O18982	—	0.973	O18982 →
P17124	—	0.973	P17124 →
Q76MS7	—	0.973	Q76MS7 →
B0UXR0	—	0.973	B0UXR0 →
D4A7K7	—	0.973	D4A7K7 →